Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.50 |
| ▸ | PLAU | P00749 | 6/20 | 0.50 |
| ▸ | PLG | P00747 | 4/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.50 |
| ▸ | KLK1 | P06870 | 2/20 | 0.50 |
| ▸ | F12 | P00748 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 3/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.47 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19479025 | 0.82 | MAPT (0.51) | F2 | |
| SCHEMBL17654807 | 0.82 | MAPT (0.51) | F2 | |
| SCHEMBL19430950 | 0.79 | PRSS1 (0.59) | F2PRSS1PLAUPLGF10 | |
| SCHEMBL19479048 | 0.77 | PRSS1 (0.60) | F2PRSS1PLAUPLGF10 | |
| SCHEMBL10940056 | 0.77 | F12 (0.52) | F2PRSS1PLAUPLGKLKB1 | |
| SCHEMBL31546801 | 0.76 | PRSS1 (0.68) | F2PRSS1PLAUPLGKLKB1 | |
| SCHEMBL3368290 | 0.76 | PRSS1 (0.68) | F2PRSS1PLAUPLGKLKB1 | |
| SCHEMBL19479031 | 0.76 | PRMT1 (0.61) | F2PRSS1PLAUPLGF10 | |
| Hydrochloric Acid SCHEMBL10642974 | 0.76 | PRSS1 (0.61) | F2PRSS1PLAUPLGF10 | |
| SCHEMBL19430548 | 0.76 | PRMT1 (0.61) | F2PRSS1PLAUPLGF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-02-16 | — | — | US | disclosed |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | U niversity of Virginia Patent Foundation (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3436451-B1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20200308159-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHYNKX THERAPEUTICS, LLC | 2020-10-01 | — | — | US | disclosed |
| US-20170298032-A1 | SPHINGOSINE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-19 | — | — | US | disclosed |
| WO-2017172989-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | THORPE STEVEN BRANDON (US) | 2017-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308159-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHK1, SPHK2, S1PR2 | F2 731/4885PRSS1 562/4885PLAU 860/4885 |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHK1, SPHK2, S1PR2 | F2 731/4885PRSS1 562/4885PLAU 860/4885 |
| US-20170298032-A1 | SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, S1PR2 | F2 3957/4885PRSS1 568/4885PLAU 963/4885 |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | F2 731/4885PRSS1 562/4885PLAU 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.